Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wesley R Armstrong

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of the National Comprehensive Cancer Network : JNCCN|February 16, 2026
Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical ProstatectomyJohn Nikitas, Clayton P Smith, Wesley R Armstrong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 29, 2021
Tumor Sink Effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?Andrei Gafita, Hui Wang, Andrew Robertson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2021
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohortJeremie Calais, Andrei Gafita, Matthias Eiber, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 22, 2019
Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletionIrmina A Elliott, Amanda M Dann, Shili Xu, et al.
JAMA Oncology|September 16, 2021
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging TrialThomas A Hope, Matthias Eiber, Wesley R Armstrong, et al.
The Lancet. Oncology|July 11, 2021
Nomograms to predict outcomes after <sup>177</sup>Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective studyAndrei Gafita, Jeremie Calais, Tristan R Grogan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 12, 2023
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate CancerLisa M Gudenkauf, Melody N Chavez, Melinda Leigh Maconi, et al.
European Urology|July 23, 2023
Presurgical <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging TrialLoïc Djaïleb, Wesley R Armstrong, Daniel Thompson, et al.
JCO Precision Oncology|July 16, 2024
Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective StudyJohn Nikitas, Kritika Subramanian, Nimrod Barashi Gozal, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of the National Comprehensive Cancer Network : JNCCN|February 16, 2026
Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical ProstatectomyJohn Nikitas, Clayton P Smith, Wesley R Armstrong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 29, 2021
Tumor Sink Effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?Andrei Gafita, Hui Wang, Andrew Robertson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2021
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohortJeremie Calais, Andrei Gafita, Matthias Eiber, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 22, 2019
Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletionIrmina A Elliott, Amanda M Dann, Shili Xu, et al.
JAMA Oncology|September 16, 2021
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging TrialThomas A Hope, Matthias Eiber, Wesley R Armstrong, et al.
The Lancet. Oncology|July 11, 2021
Nomograms to predict outcomes after <sup>177</sup>Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective studyAndrei Gafita, Jeremie Calais, Tristan R Grogan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 12, 2023
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate CancerLisa M Gudenkauf, Melody N Chavez, Melinda Leigh Maconi, et al.
European Urology|July 23, 2023
Presurgical <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging TrialLoïc Djaïleb, Wesley R Armstrong, Daniel Thompson, et al.
JCO Precision Oncology|July 16, 2024
Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective StudyJohn Nikitas, Kritika Subramanian, Nimrod Barashi Gozal, et al.
Pageof 3